Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCI
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAssiut University
About this trial
To evaluate the diagnostic value of the selected emerging biomarkers in predicting the no-reflow phenomenon among patients presenting with STEMI undergoing primary PCI. These biomarkers include:
HbA1c/C-peptide ratio
Albumin-bilirubin (ALBI) score.
Neutrophil/HDL ratio
Eligibility criteria
Qualifiers
Age ≥ 18 years
Suitable for and undergoing timely primary PCI based on symptoms and clinical judgment
Provision of informed consent
Disqualifiers
History of previous MI, PCI, or CABG
Known chronic inflammatory or autoimmune diseases
Advanced renal or hepatic failure
Active infection or malignancy at presentation
Trial design
Treatments tested in this trial
- HbA1c/C-peptide ratio Albumin-bilirubin (ALBI) score. Neutrophil/HDL ratio
Treatment groups
114 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov